After the media reports, which claimed that Donald Trump was attempting to poach the research from the German company, Germany has staked the claim to their ongoing work on inventing vaccines against coronavirus on Sunday. A spokesperson for economy ministry said that the German government has a keen interest in developing vaccines in Europe and Germany. The ministry also indicated that the government at the capability to analyze overseas takeovers of the German companies, particularly when it is about national or European safety.
Based on a report in Welt am Sonntag newspaper, it is mentioned that the president of the United States is attempting to obtain absolute rights to the promising vaccine to fight the coronavirus threat, which is now responsible for 6,000 deaths. Currently, CureVac, a biotech firm, is working on it.
The front page of Die Welt shows a headline that read “Trump versus Berlin”. A source close to the German government has stated that the US president attempted because he wanted that the vaccine would only for the United States.
However, a US official has said to AFP that the report was recklessly overplayed, and the US government has already spoken with a lot of companies that declare they can aid in developing a vaccine, and most of those companies received a decent amount of funding from US investors. The official disagreed that the United States was looking to keep a promising vaccine for itself. They would talk to any company which could aid them, and any discovered solution can be shared with the entire world.
On the other hand, the CureVac investors told the German media that they wouldn’t sell vaccine to any country. The CEO of the primary investor, Christof Hettich, said that they wanted to develop a vaccine for the entire world to fight coronavirus. CureVac was first founded in 2000 and is located in Thuringia, a state of Germany.